UBS Group’s Xenetic Biosciences, Inc. Warrants XBIOW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1
| Closed | -$14 | – | 10466 |
|
|
2024
Q2 | $14 | Hold |
1
| – | – | ﹤0.01% | 9332 |
|
|
2024
Q1 | $0 | Buy |
+1
| New | +$11 | ﹤0.01% | 10269 |
|
|
2023
Q2 | – | Sell |
-977
| Closed | -$76 | – | 9948 |
|
|
2023
Q1 | $76 | Sell |
977
-500
| -34% | -$521 | ﹤0.01% | 9281 |
|
|
2022
Q4 | $2.95K | Buy |
1,477
+100
| +7% | +$88 | ﹤0.01% | 9595 |
|
|
2022
Q3 | $3K | Hold |
1,377
| – | – | ﹤0.01% | 9616 |
|
|
2022
Q2 | $3K | Hold |
1,377
| – | – | ﹤0.01% | 9400 |
|
|
2022
Q1 | $1K | Sell |
1,377
-99
| -7% | -$97 | ﹤0.01% | 9979 |
|
|
2021
Q4 | $2K | Sell |
1,476
-12
| -0.8% | -$21 | ﹤0.01% | 9856 |
|
|
2021
Q3 | $3K | Sell |
1,488
-574
| -28% | -$1.06K | ﹤0.01% | 8860 |
|
|
2021
Q2 | $3K | Buy |
2,062
+133
| +7% | +$277 | ﹤0.01% | 8856 |
|
|
2021
Q1 | $3K | Buy |
1,929
+683
| +55% | +$1.79K | ﹤0.01% | 8544 |
|
|
2020
Q4 | $2K | Sell |
1,246
-24
| -2% | -$35 | ﹤0.01% | 8136 |
|
|
2020
Q3 | $1K | Hold |
1,270
| – | – | ﹤0.01% | 7860 |
|
|
2020
Q2 | $1K | Buy |
+1,270
| New | +$821 | ﹤0.01% | 7822 |
|
UBS Group's XBIOW Position: Q3 2024 in Review
UBS Group sold out of Xenetic Biosciences, Inc. Warrants (XBIOW) in Q3 2024, closing a stake of 1 share — an estimated $14 sold.
UBS Group first reported a position in XBIOW in Q2 2020 and held it in 14 quarters. The position peaked at $3K in Q3 2022. 0 funds tracked by Wall St. Rank hold XBIOW as of Q3 2024.
- UBS Group reported no remaining Xenetic Biosciences, Inc. Warrants position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 1 Xenetic Biosciences, Inc. Warrants share in Q3 2024, an estimated $14.
- UBS Group first reported a position in Xenetic Biosciences, Inc. Warrants in Q2 2020 and held it in 14 quarters.
- UBS Group's Xenetic Biosciences, Inc. Warrants position peaked at $3K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Xenetic Biosciences, Inc. Warrants as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.